A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab.

Johan HellgrenMaria Compagno StrandbergKristina KällénAnders Svenningsson

Published in: Multiple sclerosis journal - experimental, translational and clinical (2024)

We found no difference in fatigue levels between natalizumab and rituximab cohorts. Patients treated with natalizumab showed significantly better results on SDMT than patients on rituximab.

Keyphrases

multiple sclerosis
diffuse large b cell lymphoma
end stage renal disease
newly diagnosed
hodgkin lymphoma
chronic lymphocytic leukemia
ejection fraction
chronic kidney disease
sleep quality
prognostic factors
peritoneal dialysis
physical activity
depressive symptoms